Literature DB >> 26322166

Lack of new antiinfective agents: Passing into the pre-antibiotic age?

Klaus Brandenburg1, Tobias Schürholz1.   

Abstract

The lack of newly developed antibiotics, together with the increase in multi-resistance of relevant pathogenic bacteria in the last decades, represents an alarming signal for human health care worldwide. The number of severely infected persons increases not only in developing but also in highly industrialized countries. This relates in first line to the most severe form of a bacterial infection, sepsis and the septic shock syndrome, with high mortality on critical care units. No particular anti-sepsis drug is available, and the therapy with conventional antibiotics more and more fails to provide a survival benefit. Due to the fact that the pharmaceutical industry has withdrawn to a high degree from the development of anti-infectious agents, a huge challenge for health care is approaching in the 21(st) century. In this article, these problems are outlined and possible alternatives are presented which may be helpful to solve the problem.

Entities:  

Keywords:  Antibiotics; Antimicrobial peptides; Antimicrobial resistance; Cytokines; Endotoxins; Inflammation; Lipoproteins; Sepsis

Year:  2015        PMID: 26322166      PMCID: PMC4549771          DOI: 10.4331/wjbc.v6.i3.71

Source DB:  PubMed          Journal:  World J Biol Chem        ISSN: 1949-8454


  9 in total

Review 1.  [Severe sepsis--new therapeutic options].

Authors:  D Walmrath; F Grimminger; W Seeger
Journal:  Internist (Berl)       Date:  2001-12       Impact factor: 0.743

2.  Mechanisms of sepsis and insights from clinical trials.

Authors:  Nitin Seam; Anthony F Suffredini
Journal:  Drug Discov Today Dis Mech       Date:  2007

3.  Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors.

Authors:  Lena Heinbockel; Susana Sánchez-Gómez; Guillermo Martinez de Tejada; Sabine Dömming; Julius Brandenburg; Yani Kaconis; Mathias Hornef; Aline Dupont; Sebastian Marwitz; Torsten Goldmann; Martin Ernst; Thomas Gutsmann; Tobias Schürholz; Klaus Brandenburg
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

4.  10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; Daniel K Benjamin; John Bradley; Robert J Guidos; Ronald N Jones; Barbara E Murray; Robert A Bonomo; David Gilbert
Journal:  Clin Infect Dis       Date:  2013-04-17       Impact factor: 9.079

5.  Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin.

Authors:  K Brandenburg; G Jürgens; M Müller; S Fukuoka; M H Koch
Journal:  Biol Chem       Date:  2001-08       Impact factor: 3.915

6.  New antiseptic peptides to protect against endotoxin-mediated shock.

Authors:  Thomas Gutsmann; Iosu Razquin-Olazarán; Ina Kowalski; Yani Kaconis; Jörg Howe; Rainer Bartels; Mathias Hornef; Tobias Schürholz; Manfred Rössle; Susana Sanchez-Gómez; Ignacio Moriyon; Guillermo Martinez de Tejada; Klaus Brandenburg
Journal:  Antimicrob Agents Chemother       Date:  2010-07-06       Impact factor: 5.191

Review 7.  Bacterial lipopolysaccharides and innate immunity.

Authors:  C Alexander; E T Rietschel
Journal:  J Endotoxin Res       Date:  2001

8.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 9.  Strategies to improve drug development for sepsis.

Authors:  Mitchell P Fink; H Shaw Warren
Journal:  Nat Rev Drug Discov       Date:  2014-09-05       Impact factor: 84.694

  9 in total
  5 in total

Review 1.  Future Challenges in Pediatric and Neonatal Sepsis: Emerging Pathogens and Antimicrobial Resistance.

Authors:  Laura Folgori; Julia Bielicki
Journal:  J Pediatr Intensive Care       Date:  2019-01-17

Review 2.  Biosynthesis of Oxytetracycline by Streptomyces rimosus:
Past, Present and Future Directions in the Development
of Tetracycline Antibiotics.

Authors:  Hrvoje Petković; Tadeja Lukežič; Jagoda Šušković
Journal:  Food Technol Biotechnol       Date:  2017-03       Impact factor: 3.918

Review 3.  S100 Proteins as Novel Therapeutic Targets in Psoriasis and Other Autoimmune Diseases.

Authors:  Katarzyna Kurpet; Grażyna Chwatko
Journal:  Molecules       Date:  2022-10-06       Impact factor: 4.927

Review 4.  The threat of antimicrobial resistance in developing countries: causes and control strategies.

Authors:  James A Ayukekbong; Michel Ntemgwa; Andrew N Atabe
Journal:  Antimicrob Resist Infect Control       Date:  2017-05-15       Impact factor: 4.887

Review 5.  Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds.

Authors:  Anja Pfalzgraff; Klaus Brandenburg; Günther Weindl
Journal:  Front Pharmacol       Date:  2018-03-28       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.